If we've got less than 50% of patients who are seen by a nephrologist before they end up in one of our dialysis clinics for greater than 12 months before the onset of their kidney disease, and we have hesitation for any number of reasons for maximally prescribing RAS inhibition in the patients that we actually see, the other 50% or so that actually we do see in our clinic
The main reasons for this include the enterohepatic circulation phenomena, hepatic first-pass effect, and inadequate permeability (Zhang et al., 2004a
95% medication adherence in the first month 84% of prescribed patients engage with in-app content 56% use Med Tracker (where side effects can also be tracked) 56% engage in meal logging, with an average of 35 meals logged in the first month Patients log weight 1-2 times per week, on average, over the first 8 weeks of treatment Patients use Noom Move workouts an average of 6.9 times in the first month 45% engage with side-effect support in Nooms "Success Kit" Noom appreciates the potential of the new PDURS framework because it provides a way to put a software product on the drug label in an evidence-based way
Another area where the L-carnitine appears promising: skin healing
Also, PRMT5 knockdown impairs the self-renewal ability of GBM cells and promotes apoptosis